TRVI

+ Watchlist + Portfolio

Trevi Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.81
52-Week Range: $6.93 – $20.22
Market Cap: $2.60B
P/E (TTM): —
EPS (TTM): -0.35
Dividend Yield: —

Advanced Metrics

Price/Book: 8.09
PEG Ratio: —
Return on Equity: -19.66%
Return on Assets: -13.82%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 37.28
Debt/Equity: 0.00
Total Debt: $605.00K
Free Cash Flow: $-33.28M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.36B

TRVI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$19.83M	$23.68M	$39.38M	$33.48M
Selling, General & Admin	$10.07M	$10.24M	$12.15M	$15.85M
Operating Expenses	$29.91M	$33.92M	$51.52M	$49.33M
Operating Income	-$29.91M	-$33.92M	-$51.52M	-$49.33M
EBITDA	-$27.98M	-$28.58M	-$47.79M	-$42.68M
Pretax Income	-$29.19M	-$29.10M	-$47.94M	-$42.82M
Income Tax	-$36.00K	-$32.00K	-$30.00K	-$64.00K
Net Income	-$29.15M	-$29.07M	-$47.91M	-$42.76M
Diluted EPS	-0.45	-0.29	-0.47	-0.32
Diluted Shares	64.54M	99.03M	101.97M	134.75M

TRVI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.59M	$32.40M	$34.10M	$18.91M
Current Assets	$122.62M	$87.55M	$109.43M	$191.66M
Total Assets	$123.02M	$89.40M	$110.90M	$193.44M
Current Liabilities	$13.40M	$5.82M	$10.51M	$9.75M
Long-Term Debt	$2.15M	—	—	—
Total Debt	$9.18M	$1.34M	$1.03M	$753.00K
Total Liabilities	$15.56M	$6.86M	$11.26M	$10.20M
Retained Earnings	-$210.07M	-$239.13M	-$287.05M	-$329.80M
Shareholders' Equity	$107.46M	$82.55M	$99.64M	$183.24M
Working Capital	$109.22M	$81.72M	$98.92M	$181.91M

TRVI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.18M	-$31.71M	-$38.26M	-$42.09M
Capital Expenditure	-$159.00K	-$137.00K	-$35.00K	-$12.00K
Free Cash Flow	-$28.33M	-$31.85M	-$38.29M	-$42.10M
Depreciation & Amortisation	$43.00K	$123.00K	$147.00K	$144.00K
Stock-Based Compensation	$2.33M	$2.25M	$3.59M	$5.18M
Investing Cash Flow	-$107.37M	$59.43M	-$21.53M	-$94.11M
Financing Cash Flow	$111.31M	-$7.91M	$61.48M	$121.01M
Net Change in Cash	-$24.24M	$19.81M	$1.70M	-$15.18M

TRVI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.81M	$9.39M	$10.09M	$6.19M	$9.94M
Selling, General & Admin	$3.66M	$4.33M	$3.83M	$4.03M	$4.97M
Operating Expenses	$11.47M	$13.72M	$13.92M	$10.22M	$14.91M
Operating Income	-$11.47M	-$13.72M	-$13.92M	-$10.22M	-$14.91M
EBITDA	-$11.43M	-$12.28M	-$11.78M	-$8.30M	-$14.88M
Pretax Income	-$10.35M	-$12.32M	-$11.82M	-$8.33M	-$13.21M
Income Tax	-$11.00K	-$21.00K	-$15.00K	-$16.00K	-$20.00K
Net Income	-$10.34M	-$12.30M	-$11.80M	-$8.32M	-$13.19M
Diluted EPS	-0.09	-0.09	-0.08	-0.06	-0.09
Diluted Shares	117.61M	130.35M	145.10M	145.50M	145.59M

TRVI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$19.37M	$117.06M	$56.87M	$18.91M	$19.41M
Current Assets	$105.62M	$207.23M	$198.30M	$191.66M	$176.12M
Total Assets	$107.00M	$208.34M	$199.36M	$193.44M	$179.61M
Current Liabilities	$6.87M	$9.24M	$9.04M	$9.75M	$7.12M
Total Debt	$957.00K	$891.00K	$823.00K	$753.00K	$682.00K
Total Liabilities	$7.55M	$9.85M	$9.57M	$10.20M	$7.48M
Retained Earnings	-$297.38M	-$309.69M	-$321.49M	-$329.80M	-$343.00M
Shareholders' Equity	$99.46M	$198.49M	$189.79M	$183.24M	$172.13M
Working Capital	$98.75M	$197.99M	$189.26M	$181.91M	$169.01M

TRVI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$13.48M	-$10.10M	-$10.88M	-$7.63M	-$16.69M
Capital Expenditure	—	—	—	—	-$102.00K
Free Cash Flow	-$13.48M	-$10.10M	-$10.89M	-$7.63M	-$16.79M
Depreciation & Amortisation	$37.00K	$38.00K	$38.00K	$31.00K	$34.00K
Stock-Based Compensation	$1.21M	$1.38M	$1.24M	$1.35M	$2.19M
Investing Cash Flow	-$9.95M	-$2.61M	-$50.94M	-$30.61M	$16.96M
Financing Cash Flow	$8.71M	$110.39M	$1.63M	$284.00K	$222.00K
Net Change in Cash	-$14.72M	$97.68M	-$60.19M	-$37.95M	$498.00K

Market Snapshot

About

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious neurologically mediated conditions. The company is advancing Haduvio, an investigational therapy for chronic pruritus associated with various underlying conditions. Trevi is working to address significant unmet medical needs in pruritus and other chronic conditions.